Vilela-Martin José Fernando, Giollo-Junior Luiz Tadeu, Chiappa Gaspar Rogério, Cipriano-Junior Gerson, Vieira Paulo José Cardoso, dos Santos Ricardi Fábio, Paz-Landim Manoel Ildefonso, de Andrade Days Oliveira, Cestário Elizabeth do Espírito Santo, Cosenso-Martin Luciana Neves, Yugar-Toledo Juan Carlos, Cipullo José Paulo
Internal Medicine Department and Hospital de Base, Hypertension Clinic, Medical School in São José do Rio Preto (FAMERP), Av Anísio Haddad 7700 casa 129, Jd das Palmeiras, 15093-000, São José do Rio Preto, SP, Brazil.
Cardiology Division, Federal University of Rio Grande do Sul (UFRS), Porto Alegre, Brazil.
Trials. 2016 Mar 29;17:168. doi: 10.1186/s13063-016-1302-8.
Resistant hypertension (RH) treatment requires an adequate and intense therapeutic approach. However, the results are not always satisfactory despite intensive treatment. Of the different pathophysiological mechanisms involved in the pathogenesis of RH, sympathetic overstimulation and therapies that block the sympathetic system have been widely studied. These approaches, however, are invasive and expensive. Another possible approach is by transcutaneous electrical nerve stimulation (TENS), a noninvasive method that modulates activity by using low-frequency transcutaneous electrical stimulation to inhibit primary afferent pathways. Thus, the current study will evaluate the effect of applying TENS in the cervicothoracic region of subjects with RH and will seek to develop a new low-cost and readily available therapy to treat this group of hypertensive individuals.
METHODS/DESIGN: This is a randomized, single blind (subject), parallel-assignment study controlled with a sham group and including participants aged 40 to 70 years with resistant hypertension. The trial has two arms: the treatment and control (sham group). The treatment group will be submitted to the stimulation procedure (TENS). The sham group will not be submitted to stimulation. The primary outcomes will be a reduction in the peripheral blood pressure and adverse events. The secondary outcomes will be a reduction the central blood pressure. The study will last 30 days. The sample size was calculated assuming an alpha error of 5 % to reject the null hypothesis with a statistical power of 80 %, thereby resulting in 28 participants per group (intervention versus sham).
In recent decades, RH has become very common and costly. Adequate control requires several drugs, and in many cases, treatment is not successful. Sympathetic nervous system inhibition by renal denervation and central inhibition have significant effects in reducing BP; however, these treatments are costly and invasive. Another type of sympathetic nervous system inhibition can also be noninvasively achieved by electric current. Therefore, the application of TENS may be a new therapeutic option for treating resistant hypertensive individuals.
Clinical Trials NCT02365974.
难治性高血压(RH)的治疗需要充分且强化的治疗方法。然而,尽管进行了强化治疗,结果却并非总是令人满意。在RH发病机制中涉及的不同病理生理机制中,交感神经过度刺激以及阻断交感神经系统的疗法已得到广泛研究。然而,这些方法具有侵入性且费用高昂。另一种可能的方法是经皮电神经刺激(TENS),这是一种非侵入性方法,通过使用低频经皮电刺激来抑制初级传入通路,从而调节活动。因此,本研究将评估在RH患者的颈胸区域应用TENS的效果,并试图开发一种新的低成本且易于获得的疗法来治疗这组高血压患者。
方法/设计:这是一项随机、单盲(受试者)、平行分组研究,设有假手术组作为对照,纳入年龄在40至70岁的难治性高血压患者。该试验分为两组:治疗组和对照组(假手术组)。治疗组将接受刺激程序(TENS)。假手术组将不接受刺激。主要结局将是外周血压降低和不良事件。次要结局将是中心血压降低。该研究将持续30天。样本量的计算假设α错误为5%,以80%的统计功效拒绝零假设,从而每组有28名参与者(干预组与假手术组)。
近几十年来,RH变得非常普遍且代价高昂。充分控制需要多种药物,并且在许多情况下,治疗并不成功。通过肾去神经支配抑制交感神经系统和中枢抑制在降低血压方面有显著效果;然而,这些治疗费用高昂且具有侵入性。另一种类型的交感神经系统抑制也可以通过电流非侵入性地实现。因此,TENS的应用可能是治疗难治性高血压患者的一种新的治疗选择。
临床试验编号NCT02365974。